



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Minutes

Regular Board Meeting

Wednesday, August 14, 2024
Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
1.	Call to Order	03
2.	Invocation & Pledge of Allegiance	03
3.	Quorum Call	03
4.	Call for Additional Agenda Items & Adoption of Agenda	05
5.	Consideration of Draft Minutes from Previous Meeting	05
6.	Report on Action Items	05
7.	Confirmation of Acts	05
8.	Opportunity for Public Comment	05
9.	Special Orders of the Day	05
10.	Committee Reports	
	A. Finance	06
	B. Application Review	06
	C. Reciprocity	06
	D. Violations	07
	E. Impairment	08
	F. Reinstatement	10
	G. Tripartite	10
	H. Regulation Revision	10
	I. Executive	10
11.	Staff Reports	
	A. General Counsel	15
	B. Executive Director	17
12.	New Agenda Items Added During Meeting	18
13.	Announcements	18
14.	Adjourn	18

The Louisiana Board of Pharmacy (the “Board”) convened a regular meeting on Wednesday, August 14, 2024 at the Louisiana Board of Pharmacy located at 3388 Brentwood Drive in Baton Rouge, Louisiana 70809. The meeting was held pursuant to public notice, each member received notice, and public notice was properly posted.

1. Call to Order

Mr. Marty McKay, President, called the meeting to order at 9:10 a.m.

2. Invocation & Pledge of Allegiance

Dr. J. Robert Cloud delivered the invocation and Mr. Don L. Resweber led the group in the Pledge of Allegiance.

3. Quorum Call

Mr. McKay announced recent appointments to the Board. The terms of five Louisiana Board of Pharmacy members expired on June 30, 2024. Governor Jeff Landry reappointed two members and named three new members to the Board. He also reappointed the consumer member, who serves at the pleasure of the governor.

- For District 3, Mr. Richard A. “Andy” Soileau, from New Iberia, LA, was appointed to replace Mr. Blake P. Pitre, from Houma, LA, who completed 42 years of service to the Board.
- For District 4, Dr. David G. Collins, from Shreveport, LA, was appointed to replace Mr. Rhonny K. Valentine, from Natchitoches, LA, who completed 12 years of service to the Board.
- For District 5, Dr. J. Robert Cloud, from Calhoun, LA, was reappointed to another term.
- For District 7, Mr. Kevin LaGrange, from Lafayette, LA, was reappointed to another term.
- For District 8, Mr. Robert A. “Butch” Ray, from Pineville, LA, was appointed to replace Mr. Robert C. “Rock” LeBas, from Opelousas, LA, who completed six years of service to the Board.
- For the consumer member, Mr. Don L. Resweber, from St. Martinville, LA, was reappointed to serve at the pleasure of the governor. Mr. Resweber has served as the consumer member since November 2, 2011.

The terms for all five district members appointed will expire on June 30, 2030. On behalf of the Board, Mr. McKay welcomed the new members.

Mr. McKay also announced that on August 5, 2024, Dr. Jordan T. Bergeaux began her service to the Board as a Pharmacist-Compliance Officer for southwest Louisiana. Dr. Bergeaux replaces Mr. Huey J. Savoie who announced his retirement from the Board after 22 years of service. Mr. Savoie’s last day of work for the Board was on August 9, 2024.

Mr. McKay then called upon Mr. Joe Fontenot, to call the roll of members to establish a quorum.

Members Present:

Dr. J. Robert Cloud
Dr. David G. Collins
Mr. David A. Darce
Ms. Jennifer E. Dupree
Ms. Jacqueline L. Hall
Mr. W. Charles Jones
Mr. Kevin LaGrange
Mr. Richard Mannino
Mr. Marty R. McKay
Ms. Chris B. Melancon
Mr. J. Troy Menard
Mr. Anthony G. Mercante
Mr. Robert A. "Butch" Ray
Mr. Don L. Resweber
Mr. Richard A. "Andy" Soileau
Dr. Raymond J. Strong

Members Absent:

Mr. Richard M. Indovina, Jr.

Staff Present:

Mr. M. Joseph Fontenot Jr., Executive Director
Mr. Carlos M. Finalet, III, General Counsel
Mr. Benjamin S. Whaley, Chief Compliance Officer
Dr. Jordan T. Bergeaux, Compliance Officer
Ms. Sarah B. Stevens, Director of Licensing
Ms. Kelley Villeneuve, Office Manager

Guests:

Ms. Martha H. Hegwood
Mr. Malcolm J. Broussard – Hygeia Solutions
Ms. Sarah Perkins - BSW
Mr. N. Ryan LaBarbera – Albertsons
Ms. Christine L. LaBarbera – Cardinal Health
Ms. Shelly Dupre – Louisiana Alliance of Retail Pharmacies
Mr. Russell Champagne – Champagne & Co.
Ms. Penny Scruggins - Champagne & Co.
Mr. Paul D. Menasco - Ochsner

Mr. Fontenot certified 16 members were present, constituting a quorum for the conduct of official business.

4. Call for Additional Agenda Items & Adoption of Agenda

Mr. McKay asked if there were any additional agenda items to be added; none were requested. Without objection, the members adopted the posted agenda dated August 8, 2024. There were no objections to Mr. McKay's request for authority to re-order the agenda should the president determine it appropriate to do so.

5. Consideration of Draft Minutes from Previous Meeting

Mr. McKay reminded the members they had received the draft minutes from the regular Board meeting held on May 8, 2024. With no objections, he waived the reading of the draft minutes. With no requests for amendments or corrections, and with no objection, Mr. McKay declared the minutes were approved as presented.

6. Report on Action Items

Mr. McKay called upon Mr. Fontenot for the report. Mr. Fontenot directed the members to the report in their meeting materials which provided an update on the current status of eight regulatory projects and two legislative proposals. The members had no questions and Mr. Fontenot concluded his report.

7. Confirmation of Acts

Pursuant to Mr. McKay's declaration that the officers, members and committees, and executive director had attended to the business of the Board since their last meeting in accordance with policies and procedures previously approved by the Board, Ms. Hall moved,

***Resolved**, that the decisions made and the actions taken by the Board officers, members and committees, and executive director in the general conduct and transactions of Board business since May 8, 2024 are approved, adopted, and ratified by the entire Board.*

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

8. Opportunity for Public Comment

Mr. McKay reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present; none were offered.

*** Statement of Purpose**

Mr. McKay reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their legislative mandate in mind as they considered all the matters before them.

9. Special Orders of the Day

Mr. McKay presented a Gold Pharmacist Certificate to Ms. Martha Holmes Hegwood, PST.010472 noting during the presentation a synopsis of her professional service. The members and guests congratulated Ms. Hegwood with generous applause.

10. Committee Reports

A. Finance Committee

Mr. McKay called upon Mr. Resweber for the committee report. Mr. Resweber introduced the Board's certified public accountants – Mr. Russell F. Champagne, CPA and Ms. Penny A. Scruggins, CPA with Champagne and Company, LLC to present and review the *Compiled Financial Statements for Fiscal Year 2023-2024* which was included in the meeting materials. Mr. Champagne and Ms. Scruggins reviewed the report and answered questions from the members.

Mr. Resweber informed the members that the committee had reviewed the report the previous day and voted to recommend acceptance of the report, subject to legislative audit. On behalf of the committee, he moved,

Resolved, to accept the Compiled Financial Statements for Fiscal Year 2023-2024 as the Board's final report, subject to legislative audit.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Mr. Resweber concluded his report by recognizing the other members of the committee – Ms. Melancon and Mr. Jones.

B. Application Review Committee

Mr. McKay called upon Dr. Cloud for the committee report. Dr. Cloud reported the committee last met on February 20, 2024 and since that meeting the Board has not received any applications which require committee consideration, and therefore, have not met.

Dr. Cloud concluded his report by recognizing the other members of the committee – Mr. Darcy and Mr. Mannino.

C. Reciprocity Committee

Mr. McKay called upon Mr. Mannino for the committee report. Mr. Mannino reported the staff had evaluated 116 applications for pharmacist licensure by reciprocity since the last Board meeting and none of them contained information that warranted a committee level review. In conformance with policies and procedures previously approved by the Board, the staff approved the applications and issued the credentials. Mr. Mannino then directed the members to the list of new pharmacists licensed by reciprocity in their meeting materials.

Mr. Mannino concluded the report by recognizing the other committee members – Mr. Jones, Mr. LaGrange, Mr. Mercante, and Mr. Resweber.

D. Violations Committee

Mr. McKay called upon Dr. Cloud to give the committee report in Mr. Indovina's absence. Dr. Cloud reported the committee met on June 11-12, 2024 to consider several cases on their agenda. Following their interviews and subsequent deliberations, the committee developed recommendations for the Board's consideration. Dr. Cloud directed the members to copies of those proposals in their meeting materials and then presented the following cases to the members for their consideration.

Walgreen Louisiana Co, Inc, dba Walgreen Pharmacy No. 110-03047 (Baton Rouge, LA) (PHY.003245): Dr. Cloud moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its accountability for a controlled substance (CS) shortage and failure to provide effective controls and procedures to guard against theft or diversion, the Board assessed a fine of \$5,000 plus administrative and investigative costs.

Louisiana CVS Pharmacy, LLC, dba CVS Pharmacy No. 5396 (Bossier City, LA) (PHY.005963): Dr. Cloud moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its failure to provide effective controls and procedures to guard against theft or diversion of CS, for its accountability for shortages of CS, and failure to conduct a CS inventory upon discovery of a CS loss, the Board assessed a fine of \$35,000 plus administrative and investigative costs.

Louisiana CVS Pharmacy, LLC, dba CVS Pharmacy No. 4743 (Shreveport, LA) (PHY.006485): Dr. Cloud moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its failure to provide effective controls and procedures to guard against theft or diversion of CS, for its accountability for shortages of CS, and failure to conduct a CS inventory upon discovery of a CS loss, the Board assessed a fine of \$10,000 plus administrative and investigative costs.

Monique Rashae Morris (CPT.008384): Dr. Cloud moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For departing from or failing to conform to the minimal standards of acceptable and prevailing pharmacy practice while employed at CVS Pharmacy No. 4743, the Board suspended her certificate for one year beginning on August 13, 2024 and terminating on August 13, 2025, suspended the suspension, then placed her certificate on probation for the period of suspension, subject to certain conditions enumerated within the voluntary consent agreement.

Robbie James Bruce (PST.015875): Dr. Cloud moved to approve the proposed voluntary consent agreement. There was a member question and no public comments. The motion was adopted after a unanimous vote in the affirmative. For practicing with an expired license, the Board issued a letter of warning; and further, assessed administrative and investigative costs.

Brinkhaus Thrifty Way Pharmacy of Louisiana Store No. 23, Inc, dba Brinkhaus Thrifty Way Pharmacy (Sunset, LA) (PHY.005820): Dr. Cloud moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its failure to comply with Board regulations in regard to the compounding of sterile preparations, the Board assessed a fine of \$5,000 plus administrative and investigative costs.

Scottie James Knott (PST.015279): Dr. Cloud moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For his accountability as pharmacist-in-charge (PIC) for compliance with Board regulations in regard to the compounding of sterile preparations at Brinkhaus Thrifty Way Pharmacy, the Board assessed a fine of \$5,000 plus administrative costs.

Pharmacore, Inc, dba Hallandale Pharmacy (Fort Lauderdale, FL) (PHY.007866): Dr. Cloud moved to approve the proposed voluntary consent agreement. There was a member question and no public comments. The motion was adopted after a unanimous vote in the affirmative. For dispensing multiple prescriptions for drug products to Louisiana residents that did not meet Louisiana standards, the Board assessed a fine of \$53,790 plus administrative and investigative costs.

Gary Gilbert Koesten (PST.017432): Dr. Cloud moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For his accountability as PIC of Hallandale Pharmacy in regard to the dispensing of multiple prescriptions for drug products to Louisiana residents that did not meet Louisiana standards, the Board assessed a fine of \$5,000 plus administrative costs.

Dr. Cloud concluded the report by advising of the next scheduled committee meeting to consider 55 cases on September 17-18, 2024. Dr. Cloud then recognized the other committee members – Mr. Indovina, Ms. Hall, and Mr. Mercante.

E. Impairment Committee

Mr. McKay called upon Ms. Hall for the committee report. Ms. Hall reported the committee met the previous day. Following their interviews and subsequent deliberations, the committee developed recommendations for the Board's consideration. Ms. Hall then presented the following cases:

Courtney Elizabeth-Marie McNeal (PST.022118): Ms. Hall moved to remove Article 2-e imposed by her May 25, 2023 Board Order, thereby allowing her to serve as pharmacist-in-charge of a pharmacy. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted her request for modification of previous orders by removing Article 2-e imposed from her May 25, 2023 Board Order.

Brent Van Landry (PST.017440): Ms. Hall moved to remove all probationary conditions imposed by the August 18, 2021 Board Order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted his request for modification of previous orders by removing all terms and conditions of his probation imposed from his August 18, 2021 Board Order, and restored his license to active and unrestricted status.

Sara Gene Fletcher Feucht (CPT.005979): Ms. Hall moved to place her credential under the standard terms of the Impairment Recovery Program with a 5-year period of probation. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board suspended her certificate for five years beginning on August 14, 2024 and terminating on August 14, 2029, suspended the suspension, then placed her certificate on probation for the period of suspension, subject to certain conditions enumerated within the voluntary consent agreement.

Ms. Hall reported that Board staff concluded its Alcoholics Anonymous (AA) meeting attendance audit for fiscal year 2023-2024. Three practitioners were deficient in their reporting and were issued non-disciplinary letters of noncompliance to address those matters.

Ms. Hall then reported the committee reviewed and recommended the addition of two practitioners to the *List of Board-Approved Addictionists / Psychologists*. Ms. Hall then moved,

Resolved, to add Brandon P. Romano, Psy.D., M.S.C.P. and Smita Prasad, M.D., M.P.H., M.B.A., FASAM to the *List of Board-Approved Addictionists / Psychologists*.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Ms. Hall closed her report by recognizing the other committee members - Mr. Darce, Mr. Menard, Mr. Resweber and Dr. Strong.

F. Reinstatement Committee

Mr. McKay called upon Dr. Strong for the committee report. Dr. Strong reported the committee met the previous day. Following their interviews and subsequent deliberations, the committee developed recommendations for the Board's consideration. Dr. Strong then presented the following cases:

Mar'kayla Renee' Green (CPT.017269): Dr. Strong moved to approve the reinstatement of the suspended certificate with no restrictions. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted her request for reinstatement of previously suspended credential imposed from her May 8, 2024 Board Order, and restored her certificate to active and unrestricted status.

Lori Brooke Aymond (CPT.012396): Dr. Strong moved to approve the reinstatement of the lapsed certificate conditioned upon completion of certain requirements identified within the Board Order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted her request for reinstatement of the lapsed pharmacy technician certificate, conditioned upon her satisfaction of the following requirements prior to August 14, 2026: (1) acquisition of at least 250 hours of updated practical experience under the authority of a special work permit subject to certain terms; and (2) acquisition of at least 10 hours of ACPE-accredited technician-specific CPE.

Dr. Strong referred the members to the posted committee meeting agenda for a listing of all interim reinstatement actions by the committee chair and licensing staff. Dr. Strong then concluded his report by recognizing the other committee members - Ms. Dupree, Mr. LaGrange, Mr. Mannino, and Mr. Mercante.

G. Tripartite Committee

Mr. McKay stated the committee has not met and there was no report for the committee.

At this point, Mr. McKay declared a recess. It was noted the members recessed at 10:20 a.m. and reconvened at 10:45 a.m.

H. Regulation Revision Committee

Mr. McKay called upon Mr. Fontenot for the committee report. Mr. Fontenot reported that all matters were covered during the *Report on Action Items* portion of the current meeting.

I. Executive Committee

Mr. McKay reported the committee had met the previous day to consider the items on their posted agenda. He indicated Ms. Hall was prepared to offer motions on behalf of the committee and reminded the members that copies of the relevant documents were included in their meeting material.

- Consideration of Request for Approval from Stepful Pharmacy Technician Training Program of Detroit, Michigan

Mr. McKay reported the Board received a request to add Stepful of Detroit, Michigan to the *List of Board-Approved Pharmacy Technician Training Programs*. The program is accredited by ASHP/ACPE. After reviewing the request, the committee voted to recommend approval. Ms. Hall then moved,

Resolved, to approve Stepful Pharmacy Technician Training Program as a Board-Approved Pharmacy Technician Training Program contingent upon maintaining their ASHP/ACPE accredited status.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Consideration of Committee Recommendations Regarding the Policy & Procedure Manual

Mr. McKay stated that the revised USP Chapters <795> Pharmaceutical Compounding – Nonsterile Preparations and <797> Pharmaceutical Compounding – Sterile Preparations, along with new Chapters <800> Hazardous Drugs – Handling in Healthcare Settings and <825> Radiopharmaceuticals became official on November 1, 2023. He reminded the members that during the November 16, 2022 Board meeting, the Board elected to delay enforcement of these current USP chapters until November 1, 2024.

Mr. McKay then explained, the Board participates in the NABP Multistate Pharmacy Inspection Blueprint Program. NABP maintains a current inspection form blueprint which encompasses the current minimum standards for USP Chapters <795>, <797>, <800>, and <825>. As a Blueprint state, the Board's compliance officers use the blueprint inspection forms in applicable situations. The blueprint inspection forms were updated by NABP last year to incorporate the USP revisions. In order to prepare for the Board's November 1, 2024 enforcement date, the compliance officers have reviewed the updated blueprint forms and are prepared to begin using the updated forms on November 1 pending Board approval. The compliance team also prepared updated inspection forms for their basic pharmacy, CDS, and DME inspections. The Executive Committee reviewed the proposed revisions and new policy and voted to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revisions of PPM.IV.B.1 through PPM.IV.B.3 and approve proposed new PPM.IV.B.2.h.

There was a discussion among the members and no public comments. The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay reported that staff reviewed the record retention schedule and has recommended changes in regard to the Credentials Division and Prescription Monitoring Program records series. The Executive Committee reviewed the

proposed policy revision and voted to recommend approval. Ms. Hall then moved,

Resolved, to *approve the proposed revision of PPM.II.D.2.a ~ Record Retention Schedule.*

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Review of the 2024 Regular Session of the Louisiana Legislature
Mr. McKay reported that on July 18, 2024, Mr. Fontenot distributed *Bulletin No. 24-02* to all pharmacies, pharmacists, interns, technicians, and technician candidates. The bulletin provides a summary of new laws passed during the 2024 Regular Session of the Louisiana Legislature which impacts the practice of pharmacy or Board operations.

Mr. McKay also reported, the two bills sponsored by the Board, HB 193 – Transfer of CDS Prescriptions and HB 204 – CDS Schedule Update, were both passed by the legislature and signed by the Governor as Acts 205 and 110 with August 1, 2024 effective dates. He then presented the following Acts impacting the practice of pharmacy or Board operations:

Act 693 transfers the Board of Pharmacy’s regulatory authority for therapeutic marijuana to the Louisiana Department of Health (LDH). Marijuana pharmacy permits will be transitioned to marijuana retail permits under the authority of LDH. The effective date of the transition will be January 1, 2025.

Act 711 which authorizes a pharmacist to dispense up to a thirty-day supply of HIV pre-exposure prophylaxis and a twenty-eight-day course of HIV post-exposure prophylaxis to any person age 17 or older in the absence of a prescription drug order pursuant to rules promulgated by LDH. The act also authorizes a pharmacist to perform a rapid HIV test or order laboratory testing for HIV infection for any person age 17 or older pursuant to rules promulgated by the department. LDH is required to promulgate rules by March 2025 to implement the provisions of this new law. Mr. McKay reported that a Board representative has been appointed to serve as part of a committee formed by LDH to assist in the development of these new regulations.

Act 246, effective October 1, 2024, creates the crime of coerced criminal abortion by means of fraud when a person knowingly and intentionally engages in the use of an abortion-inducing drug on a pregnant woman, without her knowledge or consent, with the intent to cause an abortion. The Act also adds the drugs mifepristone and misoprostol to schedule 4 of the State’s Uniform Controlled Dangerous Substances Law. The legislature directed the Board of Pharmacy to notify all pharmacists in Louisiana about the provisions of the law and to ensure pharmacists are aware that lawful prescriptions for mifepristone and misoprostol may be filled in accordance with R.S. 14:87.9(C)(6). Mr. Fontenot confirmed that Bulletin 24-01 was distributed to all

pharmacies and pharmacists notifying them in regard to the provisions of Act 246. He also confirmed publication of an article in the July 2024 edition of the Board's *Newsletter*.

Mr. McKay then directed members to the *Implementation Action Plan* for the 2024 Regular Session in their meeting materials. He noted that there are a few Acts not included in the bulletin that are included in the action plan and then gave a summary of each:

Act 192 places a requirement for each state agency to review a sufficient number of its rules each year, so that after 5 years, all the agency's rules have been reviewed. The agency must report each year to the appropriate legislative oversight committees as to which rules were reviewed and whether each rule is necessary and consistent with law and the agency's mission as well as a determination of whether the probable benefits of the rule outweigh the burdens and costs on persons regulated. The Act also mandates that each agency include on its website a description of the procedure for interested persons to petition an agency requesting the adoption, amendment, or repeal of rule. The Board promulgated a rule for such petitions in April of 2020 and Mr. Fontenot added that information on the Board's website to comply with the new mandate.

Act 253 is relative to universal occupational license recognition. Board staff reviewed the Act and compared the requirements for occupational license recognition and transfer with that of current Board of Pharmacy laws and regulations for reciprocity and license transfer. Initially staff felt no changes to our own processes were necessary but there was one area in question that was brought to the Executive Committee. Mr. McKay directed members to Act 253 included in the meeting materials. He explained, on page 2 of 5 of the Act, lines 8 and 9, one of the requirements for issuing a license to an applicant from another state is that the applicant "has held a credential in another state for at least one year." When compared with Board regulations for an applicant qualifying for a "pharmacy technician certificate" when credentialed in another state, current regulation requires being credentialed and practicing for at least one year. A consensus of the committee was that Act 253 supersedes our technician regulation and staff should process applications as such. Ms. Hall then moved,

Resolved, the Board recognizes Act 253 of the 2024 Regular Session of the Louisiana Legislature, specifically R.S. 37:52(A)(2) which requires the applicant to have held the occupational license or certification in the other state for at least one year, as superseding LAC 46:905(A)(3)(c) which requires the applicant to have held the credential by another state board of pharmacy and has been practicing for at least one year.

Mr. Fontenot provided clarification on the impact of the law change. There were several member questions and no public comments. The motion was

adopted after a unanimous vote in the affirmative.

Act 644, relative to professions and occupations, amended language in the Board's Practice Act as well as the practice acts of several other professional and occupational licensing boards. Act 644 removes the crime or offense of moral turpitude from the list offenses or violations for which the Board may take disciplinary action or deny credentialing.

- Review & Consideration of Compliance Questionnaire for the Annual Legislative Audit

Mr. McKay explained that as a state government agency, each year the Board undergoes a financial audit for the previous fiscal year. As part of the financial audit process, a *Compliance Questionnaire* must be completed. The completed questionnaire must be presented to and adopted by the Board by means of a formal resolution in an open meeting. After being adopted by the full Board, the Board's secretary and president must sign the document which is then presented to the auditor.

Mr. McKay continued by stating that Board staff prepared the Louisiana *Compliance Questionnaire* for the 2023-2024 Legislative Financial Audit and the committee reviewed the document. The completed document was included in the Board member meeting material. Ms. Hall then moved,

Resolved, to approve the Louisiana Compliance Questionnaire for the Fiscal Year 2023-2024 Legislative Financial Audit.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Review & Consideration of Annual Report

Mr. McKay directed members to the copy of the *Annual Report for Fiscal Year 2023-2024* included in the meeting materials. He advised that the committee reviewed the report and voted to recommend approval of the report and authorization of its submission and filing. Ms. Hall then moved,

Resolved, to approve the Annual Report for Fiscal Year 2023-2024, and to direct its filing with the Office of the Governor, the Health & Welfare Committees of the Senate and House of Representatives, the David Poynter Legislative Research Library, the Louisiana State Library, and its subsequent publication on the Board's website.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Exceptions Report

Mr. McKay reported Board policy permits the Board President to review and respond to requests for exceptions to laws, rules, and policies in the interim between meetings of the Board. Board Policy also permits the Executive Director, with concurrence of the Board President, to issue Special Work Permits and approve dual PIC privileges with notice to the Board at its next meeting. The committee reviewed the current “*Exceptions Report*” posted in the Board member reading room and the report is now presented to the full Board as required in policy. It does not require any action from the Board. There were no member questions or comments.

Mr. McKay then closed his report by expressing his appreciation to the other committee members - Ms. Hall, Mr. Resweber, and Mr. Indovina as well as Board staff.

11. Staff Reports

A. Report of General Counsel

Mr. McKay called upon Mr. Finalet for his report. After explaining the purpose and processes regarding staff consent agreements and surrenders for new members, Mr. Finalet presented the following proposed consent agreements and surrenders to the members for their consideration.

Brittany Tiera Glapion (CPT.016521): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report an April 2024 arrest as part of her pharmacy technician reinstatement application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

J'onese La'shae Carter (CPT.017558): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report a January 2024 arrest as part of her pharmacy technician application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Destinee Audnell Lyons (CPT.015164): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For an alleged diversion of CS, the Board revoked her credential; and further, prohibited her from applying or reapplying to practice or assist in the practice of pharmacy.

Aunjane' Lynette Renee' Sims (CPT.017349): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report a March 2024 arrest as part of her pharmacy technician application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Kenneth Norman Kellow, III (PST.022855): Ms. Hall moved to accept the voluntary active surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. In lieu of immediate administrative action on a pending matter, the Board accepted the voluntary surrender of the credential, resulting in the active suspension of the license for an indefinite period of time commencing on June 28, 2024.

Cody Lane Guitreau (PST.022345): Ms. Hall moved to accept the voluntary active surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. In lieu of immediate administrative action on a pending matter, the Board accepted the voluntary surrender of the credential, resulting in the active suspension of the license for an indefinite period of time commencing on July 5, 2024.

Tynesha Rene Walker (CPT.016952): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report a November 2023 arrest as part of her pharmacy technician renewal application for 2024-2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Tabitha Nicole Duhon (CPT.013821): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report a January 2024 arrest as part of her pharmacy technician application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Mendy Lee Tregle (CPT.014084): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report a February 2024 arrest as part of her pharmacy technician application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Marquita Nicole Carter (CPT.012454): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report a May 2024 arrest as part of her pharmacy technician renewal application for 2024-2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Alexis Morgan Edmond (CPT.014926): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to

report an April 2024 arrest as part of her pharmacy technician renewal application for 2024-2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Amber Michelle Melancon Vicknair (CPT.013743): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report an August 2023 arrest as part of her pharmacy technician renewal application for 2024-2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Jordan Beatrice Rodenbaugh (PST.021335): Ms. Hall moved to accept the voluntary active surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. In lieu of immediate administrative action on a pending matter, the Board accepted the voluntary surrender of the credential, resulting in the active suspension of the license for an indefinite period of time commencing on August 5, 2024.

Mr. Finalet then indicated completion of his report.

B. Report of the Executive Director

Mr. McKay called upon Mr. Fontenot for his report. Mr. Fontenot directed the members to the quarterly report of the Louisiana Prescription Monitoring Program (PMP) found in their meeting material, there were no member comments or questions.

Mr. Fontenot then directed the members to the requests from 20 pharmacies seeking a waiver from the duty to report zero prescription transaction reports to the PMP. Ms. Hall then moved,

Resolved, to authorize the issuance of full PMP reporting waivers to the following permits once they have executed the standard consent agreement for that purpose:

Permit No.	Permit Name
PHY.008802-NR	AHF Pharmacy
PHY.008803-NR	Animal Rx Pharmacy
PHY.008847-NR	ASPN Pharmacies 3, LLC
PHY.008876-NR	Bayvrio Pharmacy, LLC
PHY.008795-NR	CarelonRx Pharmacy, Inc
PHY.008806-NR	Chewy Pharmacy DFW, LLC
PHY.008838-NR	CoverMyMeds Pharmacy, LLC
PHY.008809-IR	ENT & Allergy of New Orleans Pharmacy
PHY.008813-IR	Express Pharmacy Solutions

PHY.008857-NR	Health Care Medical Infusion Specialties
PHY.008759-NR	Musely Compounding Pharmacy East LLC
PHY.008864-IR	Pharma Fusion, LLC
PHY.008849-NR	Propel Pharmacy Ohio, LLC
PHY.008731-NR	RPC2B, LLC
PHY.008771-NR	Southend Pharmacy
PHY.008798-NR	Undefined Pharmacy
PHY.008807-NR	URGENTMEDRX, LLC
PHY.008855-NR	Vanscoy Rare Pharmacy
PHY.008777-NR	Vital Care of Roanoke
PHY.008841-NR	Walgreens Gene & Cell Services #21574

Mr. Fontenot presented the yearly census and newly issued credential reports outlining licensing data for fiscal year 2023-2024. Members expressed shared concerns regarding the number of pharmacist licenses, pharmacy intern registrations, and independent retail pharmacies.

Mr. Fontenot advised members that the Complaint Investigation Completion Policy Monitor report was included in their meeting materials. Mr. Fontenot expressed gratitude for the Compliance Division and Mr. Finalet for their efforts in resolving cases in timely manner.

12. New Agenda Items Added During Meeting

There were no new agenda items added during the meeting.

13. Announcements

Mr. McKay directed the members to the announcements in their meeting material. He announced that the Tripartite Committee will soon resume joint initiatives with Xavier and ULM. Further, Mr. McKay announced impending plans to resume hosting Board meetings at the in-state Colleges of Pharmacy.

Mr. Fontenot reminded members of the upcoming NABP meeting and annual training requirements. Members were advised of upcoming meeting dates as well.

14. Adjourn

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board and without objection, Mr. McKay adjourned the meeting at 11:45 a.m.

Minutes prepared by Joe Fontenot and then approved as presented during the subsequent meeting on November 20, 2024.

Richard M. Indovina, Jr.
Secretary